Phosphorylation of Hsp20 Promotes Fibrotic Remodeling and Heart Failure

Cardiomyocyte-specific increases in phosphorylated Hsp20 (S16D-Hsp20) to levels similar to those observed in human failing hearts are associated with early fibrotic remodeling and depressed left ventricular function, symptoms which progress to heart failure and early death. The underlying mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardner, George T., Travers, Joshua G., Qian, Jiang, Liu, Guan-Sheng, Haghighi, Kobra, Robbins, Nathan, Jiang, Min, Li, Yutian, Fan, Guo-Chang, Rubinstein, Jack, Blaxall, Burns C., Kranias, Evangelia G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488766/
https://www.ncbi.nlm.nih.gov/pubmed/31061921
http://dx.doi.org/10.1016/j.jacbts.2018.11.007
Descripción
Sumario:Cardiomyocyte-specific increases in phosphorylated Hsp20 (S16D-Hsp20) to levels similar to those observed in human failing hearts are associated with early fibrotic remodeling and depressed left ventricular function, symptoms which progress to heart failure and early death. The underlying mechanisms appear to involve translocation of phosphorylated Hsp20 to the nucleus and upregulation of interleukin (IL)-6, which subsequently activates cardiac fibroblasts in a paracrine fashion through transcription factor STAT3 signaling. Accordingly, treatment of S16D-Hsp20 mice with a rat anti-mouse IL-6 receptor monoclonal antibody (MR16-1) attenuated interstitial fibrosis and preserved cardiac function. These findings suggest that phosphorylated Hsp20 may be a potential therapeutic target in heart failure.

Ejemplares similares